| Followers | 59 |
| Posts | 7590 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Thursday, May 06, 2021 7:02:07 AM
Xblkbk, Good points. Despite the excellent analogies to PFE, what AMRN
does not have is the distribution network that PFE has, or the "gravitas"
that PFE has with governments and health authorities around the world.
This is what I find so confounding about the absence of a BP BO of AMRN.
AMRN has done what a BP like PFE does which is to lock up the supply chain.
What AMRN has not done is created awareness of its drug and its benefits.
Will Mr. Mikhail change this in Europe? Will he be able to build a
successful distribution and sales network in Europe as well as succeed
in creating awareness of Vazkepa in Europe? I hope so. He has
experience in BP in Europe. Then, the question of whether or not
Edding will succeed in China where they seem to have a distribution
network in place, can Edding create awareness of Vascepa in China?
If both succeed it could create a tight market for the feedstock. The
endgame should remain as a BP BO. Too bad a BO did not happen prior
to Thero's expansion of the sales force which required the dilution.
Thero is the epitome of poor leadership and bad management. The big
question for me is was Mikhail brought in to manage Europe or to sell
the company?
does not have is the distribution network that PFE has, or the "gravitas"
that PFE has with governments and health authorities around the world.
This is what I find so confounding about the absence of a BP BO of AMRN.
AMRN has done what a BP like PFE does which is to lock up the supply chain.
What AMRN has not done is created awareness of its drug and its benefits.
Will Mr. Mikhail change this in Europe? Will he be able to build a
successful distribution and sales network in Europe as well as succeed
in creating awareness of Vazkepa in Europe? I hope so. He has
experience in BP in Europe. Then, the question of whether or not
Edding will succeed in China where they seem to have a distribution
network in place, can Edding create awareness of Vascepa in China?
If both succeed it could create a tight market for the feedstock. The
endgame should remain as a BP BO. Too bad a BO did not happen prior
to Thero's expansion of the sales force which required the dilution.
Thero is the epitome of poor leadership and bad management. The big
question for me is was Mikhail brought in to manage Europe or to sell
the company?
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
